Crossmark Global Holdings, Inc. Bristol Myers Squibb CO Transaction History

Crossmark Global Holdings, Inc.

$5.22 Billion
Q1 2024

A detailed history of Crossmark Global Holdings, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 317,896 shares of BMY stock, worth $12.9 Million. This represents 0.33% of its overall portfolio holdings.

Number of Shares

317,896

Previous 291,200 9.17%

Holding current value

$12.9 Million

Previous $14.9 Million 15.38%

% of portfolio

0.33%

Previous 0.31%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$47.98 - $54.4 $1.28 Million - $1.45 Million	26,696 Added 9.17%	317,896 $17.2 Million
Q4 2023 Feb 13, 2024	BUY	$48.48 - $57.85 $2.44 Million - $2.92 Million	50,406 Added 20.93%	291,200 $14.9 Million
Q3 2023 Nov 08, 2023	SELL	$57.89 - $64.73 $482,976 - $540,042	-8,343 Reduced 3.35%	240,794 $13.6 Million
Q2 2023 Jul 31, 2023	BUY	$63.71 - $70.74 $1.42 Million - $1.58 Million	22,291 Added 9.83%	249,137 $15.3 Million
Q1 2023 May 12, 2023	BUY	$65.71 - $74.53 $803,304 - $911,129	12,225 Added 5.7%	226,846 $15.7 Million

Q4 2022 Jan 19, 2023	BUY	$68.48 - $81.09 $7.98 Million - $9.46 Million	116,603 Added 118.96%	214,621 $15.4 Million
Q3 2022 Nov 01, 2022	BUY	$0.13 - $76.84 $5,869 - $3.47 Million	45,153 Added 85.41%	98,018 $6.97 Million
Q2 2022 Jul 29, 2022	BUY	$72.62 - $79.98 $429,547 - $473,081	5,915 Added 12.6%	52,865 $4.07 Million
Q1 2022 May 11, 2022	SELL	$61.48 - $73.72 $164,028 - $196,684	-2,668 Reduced 5.38%	46,950 $3.43 Million
Q4 2021 Jan 10, 2022	BUY	$53.63 - $62.52 $15,552 - $18,130	290 Added 0.59%	49,618 $3.09 Million
Q3 2021 Oct 21, 2021	BUY	$59.17 - $69.31 $2.41 Million - $2.82 Million	40,688 Added 470.93%	49,328 $2.92 Million
Q3 2021 Oct 13, 2021	SELL	$59.17 - $69.31 $2.46 Million - $2.88 Million	-41,539 Reduced 82.78%	8,640 $292,000
Q2 2021 Jul 21, 2021	SELL	$61.91 - $67.42 $374,926 - $408,295	-6,056 Reduced 10.77%	50,179 $3.35 Million
Q1 2021 Apr 15, 2021	BUY	$59.34 - $66.74 $72,276 - $81,289	1,218 Added 2.21%	56,235 $3.55 Million
Q4 2020 Jan 14, 2021	SELL	$57.74 - $65.43 $2,771 - $3,140	-48 Reduced 0.09%	55,017 $3.41 Million
Q3 2020 Oct 08, 2020	SELL	$57.43 - $63.64 $106,934 - $118,497	-1,862 Reduced 3.27%	55,065 $3.32 Million
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $265,438 - $310,323	4,842 Added 9.3%	56,927 $3.35 Million
Q1 2020 Apr 28, 2020	BUY	$46.4 - $67.43 $88,484 - $128,589	1,907 Added 3.8%	52,085 $2.9 Million
Q4 2019 Feb 06, 2020	BUY	$49.21 - $64.19 $928,199 - $1.21 Million	18,862 Added 60.23%	50,178 $3.22 Million
Q3 2019 Oct 09, 2019	SELL	$42.77 - $50.71 $288,269 - $341,785	-6,740 Reduced 17.71%	31,316 $1.59 Million
Q2 2019 Jul 09, 2019	SELL	$44.62 - $49.34 $9,191 - $10,164	-206 Reduced 0.54%	38,056 $1.73 Million
Q1 2019 May 02, 2019	SELL	$45.12 - $53.8 $70,161 - $83,659	-1,555 Reduced 3.91%	38,262 $1.83 Million
Q4 2018 Jan 31, 2019	BUY	$48.76 - $63.23 $61,437 - $79,669	1,260 Added 3.27%	39,817 $2.07 Million
Q3 2018 Nov 08, 2018	BUY	$55.19 - $62.25 $191,509 - $216,007	3,470 Added 9.89%	38,557 $2.39 Million
Q2 2018 Jul 31, 2018	SELL	$50.53 - $62.98 $311,770 - $388,586	-6,170 Reduced 14.96%	35,087 $1.94 Million
Q1 2018 Apr 16, 2018	SELL	$59.92 - $68.98 $145,725 - $167,759	-2,432 Reduced 5.57%	41,257 $2.61 Million
Q4 2017 Feb 05, 2018	BUY	$59.94 - $65.35 $41,478 - $45,222	692 Added 1.61%	43,689 $2.68 Million
Q3 2016 Oct 25, 2017	BUY	N/A	42,997	42,997 $2.74 Million

Others Institutions Holding BMY

# of Institutions

2,553

Shares Held

1.49B

Call Options Held

25.9M

Put Options Held

20M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $86B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.

Account

Crossmark Global Holdings, Inc. Bristol Myers Squibb CO Transaction History